Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406
ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for
4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary
endpoint in pediatric patients with Atopic Dermatitis (AD).